Paper454499
Plasmapheresis and lymphoplasmapheresis in the management of rheumatoid arthritis.
Wallace DJ and 6 others. Arthritis Rheum, 1979. Cited by 130 papers, by iCite.
Cite this record
ConductScience Library. Plasmapheresis and lymphoplasmapheresis in the management of rheumatoid arthritis. Papers, record 454499. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/454499
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Arthritis, Rheumatoid | Major topic |
| Leukapheresis | Major topic |
| Lymphocyte Depletion | Major topic |
| Plasmapheresis | Major topic |
| Adult | |
| Evaluation Studies as Topic | |
| Female | |
| Gold | |
| Humans | |
| Immunoglobulins | |
| Indomethacin | |
| Locomotion | |
| Male | |
| Middle Aged | |
| Penicillamine | |
| Prednisone |
Source PubMed
Cited by12
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 130 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 38858604 | The peculiar features, diversity and impact of citrulline-reactive autoantibodies. | Nat Rev Rheumatol | 2024 | https://conductscience.org/library/papers/38858604 | PubMed |
| 17684748 | Partial remission of refractory RA after Adacolumn cytapheresis: a case report. | Rheumatol Int | 2008 | https://conductscience.org/library/papers/17684748 | PubMed |
| 7388713 | Progressive rheumatoid arthritis: how far should we go with medical therapy? | Can Med Assoc J | 1980 | https://conductscience.org/library/papers/7388713 | PubMed |
| 6812780 | Apheresis therapy: spin-drying the blood. | Br Med J (Clin Res Ed) | 1982 | https://conductscience.org/library/papers/6812780 | PubMed |
| 6799037 | Removal of lymphocytes in rheumatoid arthritis. | Br Med J (Clin Res Ed) | 1981 | https://conductscience.org/library/papers/6799037 | PubMed |
| 6467849 | Lymphapheresis as compared with rest period in treatment of severe rheumatoid arthritis. | Clin Rheumatol | 1984 | https://conductscience.org/library/papers/6467849 | PubMed |
| 6236868 | Where now for therapeutic apheresis? | Br Med J (Clin Res Ed) | 1984 | https://conductscience.org/library/papers/6236868 | PubMed |
| 6177290 | Potential for plasma exchange in children. | Arch Dis Child | 1982 | https://conductscience.org/library/papers/6177290 | PubMed |
| 3449305 | Extracorporeal hydrophobic amino acid adsorbent therapy in rheumatoid arthritis. | Clin Rheumatol | 1987 | https://conductscience.org/library/papers/3449305 | PubMed |
| 3056695 | The optimum management of arthropathies. | Drugs | 1988 | https://conductscience.org/library/papers/3056695 | PubMed |
| 2178759 | Plasma exchange in Canada. The Canadian Apheresis Study Group. | CMAJ | 1990 | https://conductscience.org/library/papers/2178759 | PubMed |
| 2088644 | Apheresis enhances the selective removal of antinuclear antibodies in systemic lupus erythematosus. | Clin Rheumatol | 1990 | https://conductscience.org/library/papers/2088644 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/454499
GET https://conductscience.org/api/papers/v1/454499/authors